Blueshift Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,698
| Closed | -$400K | – | 389 |
|
|
2024
Q4 | $400K | Buy |
1,698
+631
| +59% | +$148K | 0.15% | 198 |
|
|
2024
Q3 | $293K | Buy |
+1,067
| New | +$293K | 0.07% | 284 |
|
|
2023
Q3 | – | Sell |
-3,763
| Closed | -$715K | – | 273 |
|
|
2023
Q2 | $715K | Buy |
+3,763
| New | +$715K | 0.27% | 95 |
|
|
2022
Q2 | – | Sell |
-5,506
| Closed | -$899K | – | 662 |
|
|
2022
Q1 | $899K | Sell |
5,506
-196
| -3% | -$32K | 0.08% | 293 |
|
|
2021
Q4 | $967K | Buy |
5,702
+2,276
| +66% | +$386K | 0.09% | 309 |
|
|
2021
Q3 | $647K | Buy |
+3,426
| New | +$647K | 0.04% | 542 |
|
|
2021
Q2 | – | Sell |
-6,447
| Closed | -$910K | – | 903 |
|
|
2021
Q1 | $910K | Buy |
6,447
+3,730
| +137% | +$526K | 0.09% | 296 |
|
|
2020
Q4 | $353K | Buy |
+2,717
| New | +$353K | 0.04% | 490 |
|